Please login to the form below

Not currently logged in
Email:
Password:

Wellcome Trust director Sir Mark Walport named UK’s chief scientific adviser

Will provide scientific advice direct to Prime Minister David Cameron and the cabinet

The director of research charity the Wellcome Trust Sir Mark Walport has been appointed chief scientific adviser to the UK government.

Taking up his new post in April, 2013, Sir Mark will replace Sir John Beddington in providing advice directly to Prime Minister David Cameron and the cabinet concerning scientific issues.

“Science, engineering and technology have transformed the infrastructure of the modern world, and have a vital role to play at the heart of policy making,” said Sir Mark.

"They are critical both to economic recovery and growth, and to addressing many of the greatest challenges of our time, such as environmental change and the ageing population.”

With a background in immunology, Sir Mark will play a key role in the implementation of the £180m worth of life sciences reforms in the UK announced by Cameron at the end of 2011.

He will also work with ministers, the scientific community and the media to ensure that scientific methods, risk and uncertainty are understood by the public.

Sir Mark had been director of the Wellcome Trust since 2003, leading the body in its support of scientific and medical research.

This included studies into the human genome and human brain, infectious diseases such as malaria and MRSA, and chronic diseases such as diabetes and cancer.

The Trust's chair Sir Bill Castell is to lead the board of governors in the recruitment of a new director.

He said: "Mark has led the Wellcome Trust with great distinction over a decade of extraordinary achievement, and there is nobody in Britain better placed to ensure that science plays the central role it deserves to in public policy. British science will be stronger for his appointment.”

5th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Paywatch and the market access waters
Understanding and responding to payers’ needs has become priority number one for pharma as it battles the choppy seas of the global health economy...
EY Life Sciences Sector Update
Asia-Pacific and Japan...
A roadmap to strategic drug pricing
The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. Pharma firms must identify products that will benefit from innovative pricing models, and then forge...

Infographics